EUVIMEDEUVIMED entdecken
Crossref

CARM1 orchestrates hypoxia-mediated chemoresistance through the H3R17me2a/FUS upregulation in colorectal cancer

Jhao-Lin Fu, Shih-Chieh Lin, Pei-Ling Hsu, Tzu-Chien Lin, Yu-Jing Tai, Kai-Li Chang, Yu-Ting Ko, Bo-Wen Lin, Shaw-Jenq Tsai

Drug Resistance Updates · 2026-11 · 101504

DOI: 10.1016/j.drup.2026.101504 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Drug Resistance Updates, 2026-11. Verfasst von Jhao-Lin Fu und 8 weiteren Autor:innen. Beteiligte Einrichtung: Institute of Basic Medical Sciences, College of Medicine, National Cheng Kung University, Tainan 70101, Taiwan; Department of Physiology, College of …. Die Arbeit nennt 51 Literaturangaben. Gefördert von: National Health Research Institutes, National Science and Technology Council.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Hypoxia drives chemoresistance in colorectal cancer (CRC), yet the underlying epigenetic mechanisms remain unclear. Here, we identify CARM1 as a key mediator of this response. Single-cell sequencing and patient cohort analysis show that CARM1 is overexpressed in malignant epithelial cells and correlates with poor prognosis. Mechanistically, hypoxia transcriptionally upregulates CARM1 via activation of the ERK-EGR1 signaling pathway, while concomitantly suppressing dual-specificity phosphatase 2 (DUSP2) to sustain the activation of this axis. Forced expression of wild-type but not phosphatase-dead (C257S) DUSP2 abrogated ERK-EGR1-mediated CARM1 induction. Functionally, elevated levels of CARM1 contribute to drug resistance, while knockout of CARM1 sensitized both p53 wild-type (HCT116) and p53 mutant (HT-29) cells to chemotherapy. Chromatin immunoprecipitation PCR demonstrated that CARM1-mediated asymmetric dimethylation of histone 3 arginine 17 at the FUS promoter upregulates FUS expression, thereby promoting drug resistance by reducing genotoxic stress-induced DNA damage. Notably, oxaliplatin-resistant cells, which also exhibit cross-resistance to 5-fluorouracil, maintain high CARM1/FUS levels via sustained DUSP2 suppression even in normoxia, indicating that drug-resistant cancer cells phenotypically share signaling features with hypoxia-adapted cells to maintain chemoresistance. Pharmacological inhibition of CARM1 with EZM2302 disrupted this axis and enhanced the chemotherapeutic efficacy in refractory orthotopic mouse models. Our findings demonstrate that the EGR1-CARM1-FUS axis is a critical driver of CRC chemoresistance and a potential therapeutic target.

Schlagwörter

Stichwörter der Autor:innen

Asymmetric histone H3 arginine 17 dimethylationCARM1ChemoresistanceDUSP2FUSHypoxia

Autor:innen und Institutionen

  • Institute of Basic Medical Sciences, College of Medicine, National Cheng Kung University, Tainan 70101, Taiwan; Department of Physiology, College of Medicine, National Cheng Kung University, Tainan 70101, Taiwan.
  • Institute of Basic Medical Sciences, College of Medicine, National Cheng Kung University, Tainan 70101, Taiwan; Institute of Molecular Medicine, College of Medicine, National Cheng Kung University, Tainan 70101, Taiwan.
  • Institute of Basic Medical Sciences, College of Medicine, National Cheng Kung University, Tainan 70101, Taiwan; Department of Cell Biology and Anatomy, College of Medicine, National Cheng Kung University, Tainan 70101,…
  • Institute of Basic Medical Sciences, College of Medicine, National Cheng Kung University, Tainan 70101, Taiwan.
  • Department of Physiology, College of Medicine, National Cheng Kung University, Tainan 70101, Taiwan.
  • Division of Colorectal Surgery, Department of Surgery, National Cheng Kung University Hospital, Tainan 70101, Taiwan.

Förderung

  • National Health Research Institutes
  • National Science and Technology Council

Zitieren

APA

Fu, J. L., Lin, S. C., Hsu, P. L., Lin, T. C., Tai, Y. J., Chang, K. L., Ko, Y. T., Lin, B. W., & Tsai, S. J. (2026). CARM1 orchestrates hypoxia-mediated chemoresistance through the H3R17me2a/FUS upregulation in colorectal cancer. Drug Resistance Updates, 101504. https://doi.org/10.1016/j.drup.2026.101504

Vancouver

Fu JL, Lin SC, Hsu PL, Lin TC, Tai YJ, Chang KL, et al. CARM1 orchestrates hypoxia-mediated chemoresistance through the H3R17me2a/FUS upregulation in colorectal cancer. Drug Resistance Updates. 2026:101504. doi:10.1016/j.drup.2026.101504

BibTeX
@article{Fu2026,
  author = {Fu, Jhao-Lin and Lin, Shih-Chieh and Hsu, Pei-Ling and Lin, Tzu-Chien and Tai, Yu-Jing and Chang, Kai-Li and Ko, Yu-Ting and Lin, Bo-Wen and Tsai, Shaw-Jenq},
  title = {CARM1 orchestrates hypoxia-mediated chemoresistance through the H3R17me2a/FUS upregulation in colorectal cancer},
  journal = {Drug Resistance Updates},
  year = {2026},
  pages = {101504},
  doi = {10.1016/j.drup.2026.101504}
}
Kostenlos starten →